FGF21 and Irisin as Emerging Biomarkers in Metabolic Homeostasis: Molecular Mechanisms and Clinical Applications: A Narrative Review
Keywords:
FGF21, Irisin, Metabolic homeostasis, Insulin resistance, Metabolic biomarkersAbstract
The control of metabolic homeostasis requires the proper communication between the liver, skeletal muscle, adipose tissue, brain and other metabolically active organs. Two endocrine regulators, fibroblast growth factor 21 (FGF21) and irisin, have been identified as potential markers and indicators of glucose, lipid and energy metabolism disturbances. This review summarizes the existing knowledge regarding their molecular mechanisms, clinical relevance and their possible use as metabolic markers. FGF21 is mainly secreted from the liver in response to nutritional and cellular stress and acts via the fibroblast growth factor receptors and the coreceptor called β-Klotho. It acts in various ways such as improving insulin sensitivity, fatty-acid oxidation, ketogenesis, energy expenditure and adaptive response to fasting and macronutrient imbalance. Irisin is produced by the proteolytic cleavage of fibronectin type III domain-containing protein 5, and is secreted primarily by skeletal muscle during exercise. Has been connected to brown adipocyte browning of adipose tissue, mitochondrial function, glucose uptake, thermogenesis and interaction between the muscle and the organ through integrins, AMPK, p38 MAPK, and ERK pathways. Levels of circulating FGF21 are often increased in obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease and cardiovascular/renal disease; may be a sign of compensatory resistance or metabolic stress. Reported levels of irisin are more variable likely due to differences in populations, exercise protocols, specimen handling, and analytical assays. While FGF21 analogues showed promising results in clinical trials for lipid-lowering, hepatic and anti-fibrotic benefits, irisin-based therapies are still mostly pre-clinical. Both molecules could provide complementary information for metabolic assessment and therapeutic monitoring, but their use in routine clinical practice will require standardizing the measurement method, establishing validated reference intervals, prospective studies, and testing the combination of biomarker models in various populations.